-
Mashup Score: 0Examining the Evolution of Treatment With CDK4/6 Inhibitors in Metastatic Breast Cancer - 2 hour(s) ago
Anne Favret, MD discusses the FDA approval of capivasertib in combination with fulvestrant for HR-positive, HER2-negative breast cancer.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0FDA Receives Type C Meeting Request for Pelareorep in HR+/HER2– Metastatic Breast Cancer - 4 hour(s) ago
The FDA has received a type C meeting request from Oncolytics Biotech to discuss a registration-enabling trial for pelareorep in HR+/HER2– breast cancer.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 19God's Grace: The Sheila Johnson Story - 12 hour(s) ago
BET+ ORIGINAL. After her Air Force career is cut short by a cancer diagnosis, Sheila Johnson founds an advocacy group to empower Black women and men dealing with the disease.
Source: www.amazon.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 4
Cancer is an international interdisciplinary journal publishing articles on the latest clinical cancer research findings, spanning the breadth of oncology disciplines.
Categories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 1
Those aged 18 to 40 years with invasive, HER2-positive breast cancer showed a survival benefit from upfront surgery over neoadjuvant chemotherapy.
Source: www.cancernetwork.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 8
The proposed immunohistochemistry-based quantification method allows accurate assessment of human epidermal growth factor receptor 2 (HER2) protein expression levels. The approach provides insights f…
Categories: General Medicine News, Onc News and JournalsTweet-
The proposed IHC-based quantification method accurately assesses HER2 expression levels and provides insights for predicting clinical prognosis in patients with HER2-positive breast cancer who receive trastuzumab-based adjuvant therapy. https://t.co/yAlYNlH7oy @oncoalert #BCSM https://t.co/3WURx71fth
-
-
Mashup Score: 0
Results from the INSITE trial support the utility of pegulicianine fluorescence-guided surgery during breast cancer surgery.
Source: www.cancernetwork.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0Examining the Evolution of Treatment With CDK4/6 Inhibitors in Metastatic Breast Cancer - 2 day(s) ago
Anne Favret, MD discusses the FDA approval of capivasertib in combination with fulvestrant for HR-positive, HER2-negative breast cancer.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0FDA Receives Type C Meeting Request for Pelareorep in HR+/HER2– Metastatic Breast Cancer - 2 day(s) ago
The FDA has received a type C meeting request from Oncolytics Biotech to discuss a registration-enabling trial for pelareorep in HR+/HER2– breast cancer.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 6Survival Outcomes Improve With TIL Presence in TNBC - 3 day(s) ago
An increased TIL count in the breast tissue was associated with improved distant recurrence-free survival in patients with triple-negative breast cancer.
Source: www.cancernetwork.comCategories: General Medicine News, Onc News and JournalsTweet
The arsenal of treatment options for HR-positive, HER2-negative, locally advanced or metastatic breast cancer harboring 1 or more PIK3CA, AKT1, or PTEN mutations is expanding with the addition of capivasertib plus fulvestrant. @VCSpecialists #bcsm https://t.co/FddGb0Y0LQ